Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 2,101–2,200 of 15,747
Tailoring the adjuvanticity of lipid nanoparticles by PEG lipid ratio and phospholipid modifications
Vadovics, M., Zhao, W., Daley, E. F., Lam, K., Daly, O. M., Rashid, K., Lee, H. R., Schreiner, P., Lundgreen, K. A., Gaudette, B. T., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-01958-5 · Cited by 68
Monge, S., Olmedo, C., Alejos, B., Lapeña, M. F., Sierra, M. J., Limia, A., & COVID-19 registries study group (2021) · Emerging infectious diseases · doi:10.3201/eid2710.211184 · Cited by 54
Valanparambil, R. M., Carlisle, J. W., Linderman, S. L., Akhtar, A., Millett, R. L., Lai, L., Chang, A., McCook‐Veal, A. A., Switchenko, J. M., Nasti, T. H., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02986 · Cited by 49
“mRNA vaccines BNT162b2 by Pfizer and mRNA-1273 by Moderna have more than 95% efficacy in controlling SARS-CoV-2 infection.(3,4) However, variants of concern (VOCs) have emerged, resulting in breakthrough infections.”
BackgroundPritchard, E., Matthews, P., Stoesser, N., Eyre, D., Gethings, O., Vitha, K.-D., Jones, J., House, T., VanSteenhouse, H., Bell, I., et al. (2021) · medRxiv · doi:10.1101/2021.04.22.21255913 · Cited by 61
Liangou, A., Tasoglou, A., Huber, H. J., Wistrom, C., Brody, K., Menon, P. G., Bebekoski, T., Menschel, K., Davidson-Fiedler, M., DeMarco, K., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101207 · Cited by 55
“With record breaking speed, vaccines have been developed and distributed [3].”
Khoo, N. K. H., Lim, J. M. E., Gill, U. S., de Alwis, R., Tan, N., Toh, J. Z. N., Abbott, J. E., Usai, C., Ooi, E. E., Low, J. G. H., et al. (2022) · Med · doi:10.1016/j.medj.2021.12.004 · Cited by 51
“Vaccine-induced protective efficacy is associated with their ability to induce neutralizing anti-Spike antibodies and Spike-specific T cells (3, 6, 7).”
A Population-Based Analysis of the Risk of Glomerular Disease Relapse after COVID-19 Vaccination
Canney, M., Atiquzzaman, M., Cunningham, A., Zheng, Y., Lee, E., Hawken, S., Zhao, Y.-S., & Barbour, S. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2022030258 · Cited by 43
Hamilton, A. G., Swingle, K. L., Thatte, A. S., Mukalel, A. J., Safford, H. C., Billingsley, M. M., El-Mayta, R. D., Han, X., Nachod, B. E., Joseph, R. A., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c01171 · Cited by 66
Xu, Q., Xue, J.-H., Xiao, Y., Jia, Z.-J., Wu, M., Liu, Y., Li, W.-L., Liang, X., & Yang, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.786554 · Cited by 55
“CoronaVac has been approved for emergency use in several countries and was crucial for curbing the pandemic (26); the efficacies have been reported to be 50%, 65%, 78% and 91% in clinical trials in several countries (4, 27).”
BackgroundCOVID-19 complications in males and females: recent developments
Chaturvedi, R., Lui, B., Aaronson, J. A., White, R. S., & Samuels, J. D. (2022) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2022-0027 · Cited by 59
“…three-times odds of requiring ICU admission and increased odds of death Data on comorbidities such as age, ethnicity and comorbidities not present [5] Polack et al. (2020) Placebo-controlled, observer-blinded efficacy trial Global 43,548 Males vs females Vaccine efficacy Vaccine efficacy was…”
BackgroundMethodShrestha, S., Khatri, J., Shakya, S., Danekhu, K., Khatiwada, A. P., Sah, R., Bhuvan, K. C., Paudyal, V., Khanal, S., & Rodriguez-Morales, A. J. (2021) · Drugs & Therapy Perspectives · doi:10.1007/s40267-021-00852-z · Cited by 56
Mun, C. S., Hui, L. Y., Sing, L. C., Karunakaran, R., & Veerasamy, R. (2022) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2022.103458 · Cited by 65
Chemical engineering of CRISPR–Cas systems for therapeutic application
Barber, H. M., Pater, A. A., Gagnon, K. T., Damha, M. J., & O’Reilly, D. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01086-0 · Cited by 65
“The most common method for RNA-based delivery is using LNPs, as previously demonstrated by clinically approved siRNA therapeutics 133 and mRNA vaccines 134,135 .”
Zickler, A. M., Liang, X., Gupta, D., Mamand, D. R., Luca, M. D., Corso, G., Errichelli, L., Hean, J., Sen, T., Elsharkasy, O. M., et al. (2024) · Advanced Science · doi:10.1002/advs.202407619 · Cited by 67
Use of pragmatic and explanatory trial designs in acute care research: lessons from COVID-19
Casey, J. D., Beskow, L. M., Brown, J., Brown, S. M., Gayat, É., Gong, M. N., Harhay, M. O., Jaber, S., Jentzer, J. C., Laterre, P., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00044-3 · Cited by 61
Anti-inflammatory and anti-viral actions of anionic pulmonary surfactant phospholipids
Numata, M., & Voelker, D. R. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159139 · Cited by 57
Hybrid core-shell particles for mRNA systemic delivery
Andretto, V., Repellin, M., Pujol, M., Almouazen, E., Sidi‐Boumedine, J., Granjon, T., Zhang, H., Remaut, K., Jordheim, L. P., Briançon, S., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.042 · Cited by 55
Self-citationButler, M., Tamborska, A., Wood, G. K., Ellul, M. A., Thomas, R. H., Galea, I., Pett, S. L., Singh, B., Solomon, T., Pollak, T. A., et al. (2021) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-326924 · Cited by 57
“Few cases of Bell’s palsy were reported in the BNT162b2 (Pfizer-BioNTech) trial (4 in the vaccine arm and none in the placebo arm; each arm had >20 000 participants) (4) and the mRNA-1273 (Moderna) trial (3 in the vaccine arm and one in the placebo arm; each arm had >15 000 participants) (5).”
BackgroundMethodInfluentialDeb, A., Abdelmalek, J., IWUJI, K. C., & NUGENT, K. M. (2021) · Journal of Primary Care & Community Health · doi:10.1177/21501327211029230 · Cited by 52
Murase, K. (2022) · Toxins · doi:10.3390/toxins14020078 · Cited by 65
(2022) · doi:10.1186/s12916-022-02480-4 · Cited by 43
Teran, R. A., Walblay, K., Shane, E. L., Xydis, S. N., Gretsch, S. R., Gagner, A., Samala, U., Choi, H., Zelinski, C., & Black, S. R. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16634 · Cited by 51
Sakuraba, A., Luna, A., & Micić, D. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.09.055 · Cited by 55
“3 Medications used to treat IMIDs such as GCs, csDMARDs, and b/tsDMARDs-csDMARDs combination therapy may increase the risk of severe COVID-19.”
BackgroundInfluentialStevens-Johnson syndrome post second dose of Pfizer COVID-19 vaccine: a case report
Elboraey, M. O., & Essa, E. E. S. F. (2021) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2021.06.019 · Cited by 51
Abbasi, S., Matsui-Masai, M., Yasui, F., Hayashi, A., Tockary, T. A., Mochida, Y., Akinaga, S., Kohara, M., Kataoka, K., & Uchida, S. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.03.022 · Cited by 61
Urbanowicz, R. A., Tsoleridis, T., Jackson, H. J., Cusin, L., Duncan, J. D., Chappell, J. G., Tarr, A. W., Nightingale, J., Norrish, A. R., Ikram, A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abj0847 · Cited by 49
Ning, H., Liu, G., Li, L., Liu, Q., Huang, H., & Xie, Z. (2023) · Nature Communications · doi:10.1038/s41467-023-43065-w · Cited by 53
Relapse of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine
Komaba, H., Wada, T., & Fukagawa, M. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.05.006 · Cited by 51
How Chinese Herbal Medicine Prevents Epidemics: From Ancient Pestilences to COVID-19 Pandemic
Wu, X., Zhang, W.-N., Hao, M., Liu, X., Xiao, J., Wang, T., Dong, Y.-Z., & Zhao, J. (2021) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x2150049x · Cited by 51
Bošnjak, B., Odak, I., Barros‐Martins, J., Sandrock, I., Hammerschmidt, S. I., Permanyer, M., Patzer, G. E., Georgiev, H., Jauregui, R. G., Tscherne, A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.772240 · Cited by 53
“In all PB experiments, three immunization protocols were compared (1): intranasal (na) priming and boosting (na-na) (2), intramuscular (mu) priming intra nasal boosting (mu-na) and (3) intranasal priming intramuscular boosting (na-mu).”
MethodCharge‐Conversion Strategies for Nucleic Acid Delivery
Dutta, K., Das, R., Medeiros, J., Kanjilal, P., & Thayumanavan, S. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202011103 · Cited by 54
Nel, A. E., & Miller, J. F. (2021) · ACS Nano · doi:10.1021/acsnano.1c01845 · Cited by 51
An Overview of Nanoparticle-Based Delivery Platforms for mRNA Vaccines for Treating Cancer
Yang, L., Chen, X., Wang, K., Li, L., & Zhang, H. (2024) · Vaccines · doi:10.3390/vaccines12070727 · Cited by 57
“Pfizer/BioNTech’s Comirnaty (NT162b2) and Moderna’s Spikevax (mRNA-1273) were the first mRNA products to obtain approval from the FDA or the European Medicines Agency (EMA) and have been broadly validated in clinical applications [10,11].”
BackgroundLi, P., Liu, Y., Cheng, Z., Yu, X., & Li, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113568 · Cited by 62
Self-citationDesign Strategies for and Stability of mRNA–Lipid Nanoparticle COVID-19 Vaccines
Liu, T., Tian, Y., Zheng, A., & Cui, C. (2022) · Polymers · doi:10.3390/polym14194195 · Cited by 59
Current evidence for COVID-19 therapies: a systematic literature review
Welte, T., Ambrose, L., Sibbring, G. C., Sheikh, S., Müllerová, H., & Sabir, I. N. (2021) · European Respiratory Review · doi:10.1183/16000617.0384-2020 · Cited by 49
Bagacean, C., Letestu, R., Al‐Nawakil, C., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021006215 · Cited by 51
Post-COVID-19 Pulmonary Fibrosis
Mohammadi, A., Balan, I., Yadav, S., Matos, W. F., Kharawala, A., Gaddam, M., Sarabia, N., Koneru, S. C., Suddapalli, S. K., & Marzban, S. (2022) · Cureus · doi:10.7759/cureus.22770 · Cited by 80
“Indeed, the development of a vaccine is a significant accomplishment in human history [6].”
BackgroundCOVID‐19 and the Liver: Lessons Learnt from the EAST and the WEST, A Year Later
Ekpanyapong, S., Bunchorntavakul, C., & Reddy, K. R. (2021) · Journal of Viral Hepatitis · doi:10.1111/jvh.13590 · Cited by 53
Meta‐analysis: Post‐COVID‐19 functional dyspepsia and irritable bowel syndrome
Marasco, G., Maida, M. F., Cremon, C., Barbaro, M. R., Stanghellini, V., & Barbara, G. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17513 · Cited by 60
Vaccine adjuvants for infectious disease in the clinic
Goetz, M. J., Thotathil, N., Zhao, Z., & Mitragotri, S. (2024) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10663 · Cited by 67
Haque, S., Cook, K. A., Sahay, G., & Sun, C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101694 · Cited by 55
Kahnbach, L., Lehr, D., Brandenburger, J., Mallwitz, T., Jent, S., Hannibal, S., Funk, B., & Janneck, M. (2021) · Journal of Medical Internet Research · doi:10.2196/27989 · Cited by 56
Noia, V. D., Pimpinelli, F., Renna, D., Barberi, V., Maccallini, M. T., Gariazzo, L., Pontone, M., Monti, A., Campo, F., Taraborelli, E., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2439 · Cited by 52
“30 patients refused blood draw or were lost to follow-up 30 did not receive the booster Medical history of COVID-19 (11) Worsening of clinical condition or long-term hospitalization in other institutes (9) Positive swab for SARS-CoV-2 (3) Refusal (4) Cancer-related death (2) Severe allergic reaction (1)”
BackgroundmRNA vaccine designs for optimal adjuvanticity and delivery
Mochida, Y., & Uchida, S. (2024) · RNA Biology · doi:10.1080/15476286.2024.2333123 · Cited by 63
“Systemic reactogenicity is more common after the second dose of vaccines than the first dose in humans [3,4], suggesting the involvement of adaptive immunity in reactogenicity.”
BackgroundGastrointestinal Bleeding in COVID‐19 Patients: A Systematic Review with Meta‐Analysis
Marasco, G., Maida, M. F., Morreale, G. C., Licata, M., Renzulli, M., Cremon, C., Stanghellini, V., & Barbara, G. (2021) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2021/2534975 · Cited by 61
“Recently, effective anti-COVID-19 vaccines have been developed [41, 42], and distribution is ongoing.”
Cytokine Storm Syndrome in SARS-CoV-2 Infections: A Functional Role of Mast Cells
Hafezi, B., Chan, L., Knapp, J. P., Karimi, N., Alizadeh, K., Mehrani, Y., Bridle, B. W., & Karimi, K. (2021) · Cells · doi:10.3390/cells10071761 · Cited by 56
“In roughly a year since the COVID-19 pandemic began, a handful of vaccines with evidence of protective efficacy, such as BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna), have been developed and are currently being administered in numerous countries around the world [40,41].”
BackgroundThe effect of an mRNA vaccine against COVID-19 on endothelial function and arterial stiffness
Terentes-Printzios, D. G., Gardikioti, V., Solomou, E. G., Emmanouil, E., Gourgouli, I., Xydis, P., Christopoulou, G., Georgakopoulos, C., Dima, I., Miliou, A., et al. (2022) · Hypertension Research · doi:10.1038/s41440-022-00876-6 · Cited by 52
“The first vaccine to be approved was Comirnaty (BNT162b2), a messenger ribonucleic acid (mRNA)-based vaccine that produces a membraneanchored full-length spike protein of the virus and is the first of its type to be used for widespread immunization [3].”
Backgroundvan Doremalen, N., Purushotham, J. N., Schulz, J. E., Holbrook, M. G., Bushmaker, T., Carmody, A., Port, J. R., Yinda, C. K., Okumura, A., Saturday, G. A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.09.426058 · Cited by 50
One-shot identification of SARS-CoV-2 S RBD escape mutants using yeast screening
Francino-Urdaniz, I. M., Steiner, P. J., Kirby, M. B., Zhao, F., Haas, C. M., Barman, S., Rhodes, E. R., Leonard, A. C., Peng, L., Sprenger, K. G., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109627 · Cited by 49
Björk, J., Inghammar, M., Moghaddassi, M., Rasmussen, M., Malmqvist, U., & Kahn, F. (2022) · Infectious Diseases · doi:10.1080/23744235.2021.1982144 · Cited by 51
“There has been a very rapid development of vaccines against SARS-CoV-2 and mass vaccination campaigns have been launched worldwide [1,2].”
BackgroundCoronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For
Carbone, M., Lednicky, J. A., Xiao, S., Venditti, M., & Bucci, E. M. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.12.014 · Cited by 76
mRNA vaccines in the prevention and treatment of diseases
Gu, Y., Duan, J., Yang, N., Yang, Y., & Zhao, X. (2022) · MedComm · doi:10.1002/mco2.167 · Cited by 58
On the road to ending the COVID-19 pandemic: Are we there yet?
Case, J. B., Winkler, E. S., Errico, J. M., & Diamond, M. (2021) · Virology · doi:10.1016/j.virol.2021.02.003 · Cited by 49
Caronna, E., van den Hoek, T. C., Bolay, H., García‐Azorín, D., Gago‐Veiga, A. B., Valeriani, M., Takizawa, T., Meßlinger, K., Shapiro, R. E., Goadsby, P. J., et al. (2023) · Cephalalgia · doi:10.1177/03331024221131337 · Cited by 49
“The headache incidences found in the pivotal randomized multicenter phase-3 studies on Corminaty (BNT162b2) from BioNTech/Pfizer (60), Spikevax (mRNA-1273) from Moderna (61), AZD1222 (ChAdOx1 nCoV-19) from AstraZeneca (62,63), Ad26.”
BackgroundAn update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages
Motamedi, H., Ari, M. M., Dashtbin, S., Fathollahi, M., Hossainpour, H., Alvandi, A., Moradi, J., & Abiri, R. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107763 · Cited by 56
“In general, none of these deaths were because of vaccine candidates [174].”
Vaccine efficacy and iron deficiency: an intertwined pair?
Drakesmith, H., Pasricha, S.-R., Cabantchik, I., Hershko, C., Weiss, G., Girelli, D., Stoffel, N. U., Muckenthaler, M. U., Nemeth, E., Camaschella, C., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00201-5 · Cited by 60
Li, X., Li, J., Wei, J., Du, W., Su, C., Shen, X., Zhao, A., & Xu, M. (2025) · MedComm · doi:10.1002/mco2.70414 · Cited by 72
Brisotto, G., Muraro, E., Montico, M., Corso, C., Evangelista, C., Casarotto, M., Caffau, C., Vettori, R., Cozzi, M. R., Zanussi, S., et al. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.10.035 · Cited by 57
Immunopathology and Immunopathogenesis of COVID-19, what we know and what we should learn
Shahgolzari, M., Yavari, A., Arjeini, Y., Miri, S. M., Darabi, A., Nejad, A. S. M., & Keshavarz, M. (2021) · Gene Reports · doi:10.1016/j.genrep.2021.101417 · Cited by 55
COVID-19 Vaccines and Autoimmune Hematologic Disorders
Mingot‐Castellano, M. E., Butta, N. V., Canaro, M., Solano, M. D. C. G. D. C., Sánchez‐González, B., Jiménez‐Bárcenas, R., Pascual, C., Caballero‐Navarro, G., Ureña, L. E., González‐López, T. J., et al. (2022) · Vaccines · doi:10.3390/vaccines10060961 · Cited by 49
“Although thrombocytopenia secondary to COVID-19 vaccination had not been reported as a frequent AE in the clinical trials that led to the approval of vaccines [12,39], soon afterwards, regular updates of databases highlighted occasional secondary thrombocytopenia appearance in previously healthy recipients when vaccin…”
BackgroundRecent advances in targeted delivery of non-coding RNA-based therapeutics for atherosclerosis
Li, X., Qi, H., Cui, W., Wang, Z., Fu, X., Li, T., Ma, H., Yang, Y., & Yu, T. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.07.018 · Cited by 52
Mandolesi, M., Sheward, D. J., Hanke, L., Ma, J., Pushparaj, P., Perez Vidakovics, L., Kim, C., Àdori, M., Lenart, K., Loré, K., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100252 · Cited by 50
— Invited Review — Current status, challenges and prospects for pig production in Asia
Wang, L., & Li, D. (2024) · Animal Bioscience · doi:10.5713/ab.23.0303 · Cited by 52
“The mRNA vaccine technology has made significant progress over the past two decades [50], which has recently proven effective in controlling COVID-19 [51].”
Cavanna, L., Citterio, C., Biasini, C., Madaro, S., Bacchetta, N., Lis, A., Cremona, G., Muroni, M., Bernuzzi, P., Cascio, G. L., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.035 · Cited by 53
“00% efficacy in preventing symptomatic SARSCoV-2 infection independent of age [16,17].”
Flacco, M. E., Soldato, G., Martellucci, C. A., Carota, R., Luzio, R. D., Caponetti, A., & Manzoli, L. (2021) · Vaccines · doi:10.3390/vaccines9060628 · Cited by 52
“This finding is in line with previous trials and real-world studies on healthcare workers [3,4,14], and may help, at least in part, to shorten the gap in vaccine hesitancy between males and females, the latter having shown higher reluctancy in several surveys [14,26–29].”
ResultGriva, K., Tan, K. K.-Y., Chan, F. H. F., Periakaruppan, R., Ong, B. W. L., Soh, A. S., & Chen, M. I.-C. (2021) · Vaccines · doi:10.3390/vaccines9121415 · Cited by 52
Hadjadj, J., Planas, D., Ouedrani, A., Buffier, S., Delage, L., Nguyen, Y., Bruel, T., Stolzenberg, M., Staropoli, I., Ermak, N., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221508 · Cited by 50
Regan, A. K., Arah, O. A., Fell, D. B., & Sullivan, S. G. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab626 · Cited by 53
“In addition to handwashing and social distancing measures, with the availability of highly efficacious vaccines [15-17], guidelines encouraging vaccination of pregnant individuals [18], and early results suggesting mRNA vaccine safety in pregnancy [19], effective prevention of maternal SARS-CoV-2 infection is possible.”
BackgroundGlobal diversity of policy, coverage, and demand of COVID-19 vaccines: a descriptive study
Chen, Z., Zheng, W., Wu, Q., Chen, X., Peng, C., Tian, Y., Sun, R., Dong, J., Wang, M., Zhou, X., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02333-0 · Cited by 57
“Rapid and successful development of efficacious and effective vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its variants is making it possible to manage the pandemic [4].”
BackgroundEvaluation of Messenger RNA From COVID-19 BTN162b2 and mRNA-1273 Vaccines in Human Milk
Golan, Y., Prahl, M. K., Cassidy, A. G., et al. (2021) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2021.1929 · Cited by 50
Wong, C. K. H., Mak, L., Au, I. C. H., Lai, F. T. T., Li, X., Wan, E. Y. F., Chui, C. S. L., Chan, E. W., Cheng, W. Y., Cheng, F. W. T., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.032 · Cited by 52
“Both vaccines trigger a robust adaptive immune response and the production of neutralizing antibodies.(10,11) In response to the safety signal of ALI generated from the published case reports, this pharmacovigilance study was conducted to investigate the risk and severity of ALI following COVID-19 vaccination.”
Oliver, M. J., Thomas, D., Balamchi, S., Ip, J., Naylor, K. L., Dixon, S. N., McArthur, E., Kwong, J. C., Perl, J., Atiquzzaman, M., et al. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021091262 · Cited by 50
Lives saved and hospitalizations averted by COVID-19 vaccination in New York City: a modeling study
Shoukat, A., VILCHES, T. N., Moghadas, S. M., Sah, P., Schneider, E. C., Shaff, J., Zucker, J. R., Quinn, C., Chokshi, D. A., & Galvani, A. P. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100085 · Cited by 61
What can we learn from Israel’s rapid roll out of COVID 19 vaccination?
McKee, M., & Rajan, S. (2021) · Israel Journal of Health Policy Research · doi:10.1186/s13584-021-00441-5 · Cited by 50
Recent advances in therapeutic nucleic acids and their analytical methods
Talap, J., Zhao, J. Y., Shen, M., Song, Z., Zhou, H., Kang, Y., Sun, L., Yu, L., Zeng, S., & Cai, S. (2021) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2021.114368 · Cited by 56
Genome-scale CRISPR screens identify host factors that promote human coronavirus infection
Grodzki, M., Bluhm, A. P., Schaefer, M., Tagmount, A., Russo, M., Sobh, A., Rafiee, R., Vulpe, C. D., Karst, S. M., & Norris, M. H. (2022) · Genome Medicine · doi:10.1186/s13073-022-01013-1 · Cited by 58
Current Vaccine Platforms in Enhancing T-Cell Response
Ura, T., Takeuchi, M., Kawagoe, T., Mizuki, N., Okuda, K., & Shimada, M. (2022) · Vaccines · doi:10.3390/vaccines10081367 · Cited by 60
Liu, C., Lee, J., Ta, C. N., Soroush, A., Rogers, J. R., Kim, J. H., Natarajan, K., Zucker, J. E., & Weng, C.-H. (2021) · medRxiv · doi:10.1101/2021.10.05.21264583 · Cited by 32
Perez, Y., Levy, E. R., Joshi, A. Y., Virk, A., Rodriguez-Porcel, M. G., Johnson, M. P., Roellinger, D. L., Vanichkachorn, G., Huskins, W. C., & Swift, M. D. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab926 · Cited by 58
Modulating intracellular pathways to improve non-viral delivery of RNA therapeutics
de Vyver, T. V., Smedt, S. C. D., & Raemdonck, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114041 · Cited by 51
Yewdell, J. W. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009509 · Cited by 48
Optimized circular RNA vaccines for superior cancer immunotherapy
Yu, H., Wen, Y., Yu, W., Lu, L., Yu, Y., Liu, C., Hu, Z., Fang, Z., & Huang, S. (2024) · Theranostics · doi:10.7150/thno.104698 · Cited by 57
“…International Publisher advancement can be attributed, in part, to the rapid deployment of mRNA vaccine technology during the COVID-19 pandemic [4], which significantly accelerated the clinical research and development of mRNA cancer vaccines. mRNA is now considered one of the most promising…”
Routhu, N. K., Gangadhara, S., Lai, L., Davis-Gardner, M. E., Floyd, K. A., Shiferaw, A., Bartsch, Y. C., Fischinger, S., Khoury, G., Rahman, S. A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abo0226 · Cited by 51
“Both mRNA-based vaccines, mRNA-1273 and BNT162b2, have shown ~95% efficacy in clinical trials when the circulating SARS-CoV-2 strains are the wild-type WA-1/2020 strain and near wild-type D614G variant (5, 6).”
Liu, H., Pietersz, G. A., Peter, K., & Wang, X. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01279-y · Cited by 60
Cao, L., Lou, J., Chan, S. Y., Zheng, H., Liu, C., Zhao, S., Li, Q., Mok, C. K. P., Chan, R. W. Y., Chong, M. K. C., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01877-1 · Cited by 49
“3) 32 [3] BNT162b2 mRNA 92 (88, 94) 38 [4] BNT162b2 mRNA 90 (85, 94) 43 [5] BNT162b2 mRNA 86 (81, 90) 44 [6] AZD1222 Viral vector 81 (72, 87) 38 [7] AZD1222 Viral vector 74.”
Mirtaleb, M. S., Falak, R., Heshmatnia, J., Bakhshandeh, B., Taheri, R. A., Soleimanjahi, H., & Emameh, R. Z. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109934 · Cited by 65
“Previous studies of mRNA vaccines against Zika, influenza, and rabies viruses have also shown positive effects with high immunogenicity during pregnancy of women before the pandemic [110,111].”
An Update on mRNA-Based Viral Vaccines
Jeeva, S., Kim, K., Shin, C. H., Wang, B., & Kang, S. (2021) · Vaccines · doi:10.3390/vaccines9090965 · Cited by 54
“The FDA-approved SARS-CoV-2 mRNA vaccines (mRNA-1273, BNT162b2) were reported to exhibit high efficacy of over 94% in phase 2 and 3 studies [9,96].”
BackgroundCOVID-19 vaccines in pregnancy
Nunes, M. C., & Madhi, S. A. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.04.012 · Cited by 54
“In general, the rate of systemic adverse events was higher following the second vaccine dose for both mRNA vaccines [31,36,48], as was also evident in non-pregnant individuals [14,16,58].”
Ellis, D., Brunette, N., Crawford, K. H. D., Walls, A. C., Pham, M. N., Chen, C., Herpoldt, K., Fiala, B., Murphy, M., Pettie, D., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.710263 · Cited by 47
Alam, S., Kamal, T. B., Sarker, M. M. R., Zhou, J., Rahman, S. M. A., & Mohamed, I. N. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.659577 · Cited by 55
“To worsen the issue, allocation and production in sufficient quantities and the affordability and deployment of these vaccines are also notable challenges faced by the policy makers and developers (Folegatti et al., 2020; Polack et al., 2020; Logunov et al., 2021;Wouters et al., 2021).”
BackgroundAn Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era
Pascual‐Iglesias, A., Cantón, J., Ortega‐Prieto, A. M., Jiménez-Guardeño, J. M., & Regla-Nava, J. Á. (2021) · Pathogens · doi:10.3390/pathogens10081030 · Cited by 53
Development of a rapid point-of-care test that measures neutralizing antibodies to SARS-CoV-2
Lake, D. F., Roeder, A. J., Kaleta, E. J., Jasbi, P., Pfeffer, K., Koelbela, C., Periasamy, S., Kuzmina, N. A., Bukreyev, A. A., Grys, T. E., et al. (2021) · Journal of Clinical Virology · doi:10.1016/j.jcv.2021.105024 · Cited by 50
Lozano‐Rodríguez, R., Valentín‐Quiroga, J., Ortiz, J. A., Martín‐Quirós, A., Pascual‐Iglesias, A., Terrón‐Arcos, V., Montalbán-Hernández, K. M., Casalvilla‐Dueñas, J. C., Bergón-Gutiérrez, M., Alcamí, J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110235 · Cited by 54
“…a switch to an anti-RBD neutralizing phenotype (Sokal et al., 2021), it is tempting to speculate that long-term protection already documented for the BNT162b2 vaccine (Thomas et al., 2021) is warranted, based at least in part on the restimulation of these cells during a SARS-CoV-2 reinfection.”
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.